MX2007002807A - Compuesto 2-morfolino-4-pirimidona. - Google Patents
Compuesto 2-morfolino-4-pirimidona.Info
- Publication number
- MX2007002807A MX2007002807A MX2007002807A MX2007002807A MX2007002807A MX 2007002807 A MX2007002807 A MX 2007002807A MX 2007002807 A MX2007002807 A MX 2007002807A MX 2007002807 A MX2007002807 A MX 2007002807A MX 2007002807 A MX2007002807 A MX 2007002807A
- Authority
- MX
- Mexico
- Prior art keywords
- morpholino
- integer
- alkyl
- pyrimidone compound
- pyrimidone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto representado por la formula (I), un isomero opticamente activo de el o una sal farmaceutica aceptable de el: (ver formula (I)) en donde X representa CH o N, R1 representa un alquilo de C1-C12; R2 representa un atomo de hidrogeno, o similar; R' representa un alquilo de C1-C6 o similar; q representa 0 o un numero entero de 1 a 7; Y representa un alquilo de C1-C6 o similar; p representa 0 o un numero entero de 1 a 5; R representa un 2,3-dihidroindolilo o similar; que se usa para el tratamiento preventivo y/o terapeutico de una enfermedad provocada por la hiperactividad de la tau proteina cinasa 1 tal como enfermedades neurodegenerativas (por ejemplo, la enfermedad de Alzheimer).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004296926 | 2004-09-09 | ||
PCT/JP2005/017080 WO2006028290A1 (en) | 2004-09-09 | 2005-09-09 | 2-morpholino-4-pyrimidone compound |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007002807A true MX2007002807A (es) | 2007-05-16 |
Family
ID=35385631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007002807A MX2007002807A (es) | 2004-09-09 | 2005-09-09 | Compuesto 2-morfolino-4-pirimidona. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8106045B2 (es) |
EP (3) | EP2258701A1 (es) |
JP (1) | JP5060287B2 (es) |
KR (1) | KR20070058586A (es) |
CN (1) | CN101035781A (es) |
AR (1) | AR050865A1 (es) |
AU (1) | AU2005280885B2 (es) |
BR (1) | BRPI0515628A (es) |
CA (1) | CA2578434A1 (es) |
EA (1) | EA013839B1 (es) |
IL (1) | IL181732A0 (es) |
MX (1) | MX2007002807A (es) |
NO (1) | NO20071787L (es) |
NZ (1) | NZ554300A (es) |
TW (1) | TW200621760A (es) |
WO (1) | WO2006028290A1 (es) |
ZA (1) | ZA200702266B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200740779A (en) * | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
WO2008023239A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
WO2008026046A1 (en) * | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
AR064660A1 (es) * | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
EA016687B8 (ru) | 2007-08-22 | 2012-07-30 | Астразенека Аб | Производные циклопропиламида |
AU2008297817A1 (en) | 2007-09-14 | 2009-03-19 | Mitsubishi Tanabe Pharma Corporation | 6-pyrimidinyl-pyrimid-4-one derivative |
DE102008010363A1 (de) * | 2008-02-18 | 2009-08-20 | Lang, Florian, Prof. Dr.med. | Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US9006232B2 (en) | 2009-08-13 | 2015-04-14 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives |
US8940738B2 (en) | 2009-08-13 | 2015-01-27 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone compounds |
AR078320A1 (es) | 2009-09-04 | 2011-11-02 | Biogen Idec Inc | Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres. |
KR20130004296A (ko) | 2010-02-18 | 2013-01-09 | 아스트라제네카 아베 | 시클로프로필 아미드 유도체의 제조 방법 및 그와 관련된 중간체 |
JP5784110B2 (ja) * | 2010-05-11 | 2015-09-24 | サノフイ | 置換されたn−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用 |
US8802673B2 (en) * | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
CU20130027A7 (es) | 2013-02-28 | 2014-10-30 | Ct De Neurociencias De Cuba | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
CN104974017B (zh) * | 2014-04-09 | 2017-11-17 | 上海医药工业研究院 | (1r,2s)‑2‑(3,4‑二氟苯基)环丙胺·d‑扁桃酸盐的制备方法 |
CA3031443A1 (en) | 2016-07-21 | 2018-01-25 | Biogen Ma Inc. | Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors |
CN108299252A (zh) * | 2018-04-04 | 2018-07-20 | 梯尔希(南京)药物研发有限公司 | 一种去甲肾上腺素磺酸类代谢物的合成方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2116460A1 (en) | 1993-03-02 | 1994-09-03 | Mitsubishi Chemical Corporation | Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being |
TWI241298B (en) | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
AU2001262150A1 (en) * | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
MXPA04002661A (es) * | 2001-09-21 | 2004-11-22 | Sanofi Aventis | Derivados de pirimidona 4, 3-sustituida. |
PL368671A1 (en) * | 2001-09-21 | 2005-04-04 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
KR100956052B1 (ko) | 2002-12-16 | 2010-05-06 | 미쓰비시 타나베 파마 코퍼레이션 | 3-치환-4-피리미돈 유도체 |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
SI1805164T1 (sl) * | 2004-09-29 | 2011-05-31 | Mitsubishi Tanabe Pharma Corp | 6-(piridinil)-4-pirimidonski derivati kot inhibitorji tau protein kinaze 1 |
-
2005
- 2005-09-08 TW TW094130958A patent/TW200621760A/zh unknown
- 2005-09-08 AR ARP050103749A patent/AR050865A1/es not_active Application Discontinuation
- 2005-09-09 MX MX2007002807A patent/MX2007002807A/es not_active Application Discontinuation
- 2005-09-09 EP EP10179860A patent/EP2258701A1/en not_active Withdrawn
- 2005-09-09 EP EP10179893A patent/EP2266979A1/en not_active Withdrawn
- 2005-09-09 EA EA200700572A patent/EA013839B1/ru not_active IP Right Cessation
- 2005-09-09 AU AU2005280885A patent/AU2005280885B2/en not_active Ceased
- 2005-09-09 CN CNA2005800303535A patent/CN101035781A/zh active Pending
- 2005-09-09 JP JP2007511563A patent/JP5060287B2/ja not_active Expired - Fee Related
- 2005-09-09 CA CA002578434A patent/CA2578434A1/en not_active Abandoned
- 2005-09-09 EP EP05783586A patent/EP1789414A1/en not_active Withdrawn
- 2005-09-09 WO PCT/JP2005/017080 patent/WO2006028290A1/en active Application Filing
- 2005-09-09 KR KR1020077007681A patent/KR20070058586A/ko active IP Right Grant
- 2005-09-09 NZ NZ554300A patent/NZ554300A/en not_active IP Right Cessation
- 2005-09-09 ZA ZA200702266A patent/ZA200702266B/xx unknown
- 2005-09-09 BR BRPI0515628-9A patent/BRPI0515628A/pt not_active IP Right Cessation
- 2005-09-09 US US11/573,476 patent/US8106045B2/en not_active Expired - Fee Related
-
2007
- 2007-03-06 IL IL181732A patent/IL181732A0/en unknown
- 2007-04-04 NO NO20071787A patent/NO20071787L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2258701A1 (en) | 2010-12-08 |
AU2005280885B2 (en) | 2011-09-22 |
BRPI0515628A (pt) | 2008-03-04 |
IL181732A0 (en) | 2007-07-04 |
US20090124618A1 (en) | 2009-05-14 |
CA2578434A1 (en) | 2006-03-16 |
EA013839B1 (ru) | 2010-08-30 |
KR20070058586A (ko) | 2007-06-08 |
JP2008512347A (ja) | 2008-04-24 |
NO20071787L (no) | 2007-05-09 |
NZ554300A (en) | 2009-12-24 |
AU2005280885A1 (en) | 2006-03-16 |
CN101035781A (zh) | 2007-09-12 |
AR050865A1 (es) | 2006-11-29 |
EP2266979A1 (en) | 2010-12-29 |
EP1789414A1 (en) | 2007-05-30 |
WO2006028290A1 (en) | 2006-03-16 |
EA200700572A1 (ru) | 2007-10-26 |
TW200621760A (en) | 2006-07-01 |
ZA200702266B (en) | 2008-09-25 |
US8106045B2 (en) | 2012-01-31 |
JP5060287B2 (ja) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007002807A (es) | Compuesto 2-morfolino-4-pirimidona. | |
TW200626573A (en) | Pyrimidone compound | |
EP2423207A3 (en) | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | |
WO2007092531A3 (en) | Compounds and compositions as protein kinase inhibitors | |
NO20054331L (no) | Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
ATE384061T1 (de) | Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
EA200601660A1 (ru) | Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами | |
DK1730147T3 (da) | Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme | |
NO20063787L (no) | Terapeutiske preparater | |
SE0104332D0 (sv) | Therapeutic agents | |
EA200970637A1 (ru) | 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы | |
ATE484502T1 (de) | Neue verbindungen | |
NO20064344L (no) | Caspaseinhibitorer og anvendelser derav | |
DE502004006619D1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
NO20073170L (no) | Kaspaseinhibitorer og anvendelse derav | |
CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
EA201070367A1 (ru) | Производное 6-пиримидинилпиримид-4-она | |
EA200600760A1 (ru) | Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их | |
NO20072634L (no) | Antiinfektive lipopeptider | |
TW200740428A (en) | Substituted propanamide derivatives and pharmaceutical compositions thereof | |
WO2001070683A3 (en) | 3-substituted-4-pyrimidone derivatives | |
EA201000832A1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции | |
TH80189A (th) | สารประกอบ 2-มอร์โฟลิโน-4-ไพริมิโดน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |